FDA正在要求制订一份可提供给所有患者的有关使用纳曲酮缓释注射用混悬剂治疗的用药指南。
The FDA is requiring that a medication guide about treatment with naltrexone extended-release injectable suspension be provided to all patients.
纳曲酮缓释注射用混悬剂是首个也是目前仅有的每月注射一次用于治疗酒精依赖的药物。
Naltrexone extended-release injectable suspension is the first — and currently the only — once-monthly injectable medication for alcohol dependence.
本发明涉及一种以阿奇霉素为主要成分的口服缓释干混悬剂。
The invention relates to oral sustained-release dry suspension taking azithromycin as a main ingredient.
它是以阿奇霉素为主要活性成分与药学上可接受的辅料通过制剂技术而制成的口服缓释干混悬剂。
The oral sustained-release dry suspension is prepared from the azithromycin serving as the main active ingredient and pharmaceutically acceptable supplementary materials by pharmaceutical technology.
它是以阿奇霉素为主要活性成分与药学上可接受的辅料通过制剂技术而制成的口服缓释干混悬剂。
The oral sustained-release dry suspension is prepared from the azithromycin serving as the main active ingredient and pharmaceutically acceptable supplementary materials by pharmaceutical technology.
应用推荐